These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Comparison of Ticagrelor Versus Prasugrel for Inflammation, Vascular Function, and Circulating Endothelial Progenitor Cells in Diabetic Patients With Non-ST-Segment Elevation Acute Coronary Syndrome Requiring Coronary Stenting: A Prospective, Randomized, Crossover Trial. Jeong HS; Hong SJ; Cho SA; Kim JH; Cho JY; Lee SH; Joo HJ; Park JH; Yu CW; Lim DS JACC Cardiovasc Interv; 2017 Aug; 10(16):1646-1658. PubMed ID: 28838475 [TBL] [Abstract][Full Text] [Related]
6. Real-world evidence of switching P2Y12 receptor-inhibiting therapies to prasugrel after PCI in patients with ACS: results from EFF-K registry. Kang J; Han JK; Yang HM; Park KW; Kang HJ; Koo BK; Choo EH; Lee JY; Park SD; Lim YH; Kim HM; Heo JH; Kim HS BMC Cardiovasc Disord; 2023 Jan; 23(1):6. PubMed ID: 36624388 [TBL] [Abstract][Full Text] [Related]
7. Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): the randomised, open-label, non-inferiority trial. Gimbel M; Qaderdan K; Willemsen L; Hermanides R; Bergmeijer T; de Vrey E; Heestermans T; Tjon Joe Gin M; Waalewijn R; Hofma S; den Hartog F; Jukema W; von Birgelen C; Voskuil M; Kelder J; Deneer V; Ten Berg J Lancet; 2020 Apr; 395(10233):1374-1381. PubMed ID: 32334703 [TBL] [Abstract][Full Text] [Related]
9. Comparison of prescription rates and clinical outcomes in acute coronary syndrome patients who underwent percutaneous coronary intervention using different P2Y Choe JC; Cha KS; Ahn J; Park JS; Lee HW; Oh JH; Choi JH; Lee HC; Hong TJ; Jeong MH; Int J Cardiol; 2019 Jan; 274():21-26. PubMed ID: 30224257 [TBL] [Abstract][Full Text] [Related]
10. Comparison of P2Y12 Inhibitors in Acute Coronary Syndromes in the Australian Population. Hou M; Hyun K; Chew DP; Kritharides L; Amos D; Brieger D Heart Lung Circ; 2022 Aug; 31(8):1085-1092. PubMed ID: 35589483 [TBL] [Abstract][Full Text] [Related]
11. Real-World Evidence on Disparities on the Initiation of Ticagrelor Versus Prasugrel in Patients With Acute Coronary Syndrome. Yildirim M; Mueller-Hennessen M; Milles BR; Biener M; Hund H; Frey N; Giannitsis E; Salbach C J Am Heart Assoc; 2023 Aug; 12(16):e030879. PubMed ID: 37581388 [TBL] [Abstract][Full Text] [Related]
12. Ticagrelor or Prasugrel for Patients With Acute Coronary Syndrome Treated With Percutaneous Coronary Intervention: A Prespecified Subgroup Analysis of a Randomized Clinical Trial. Coughlan JJ; Aytekin A; Lahu S; Ndrepepa G; Menichelli M; Mayer K; Wöhrle J; Bernlochner I; Gewalt S; Witzenbichler B; Hochholzer W; Sibbing D; Cassese S; Angiolillo DJ; Hemetsberger R; Valina C; Müller A; Kufner S; Liebetrau C; Xhepa E; Hapfelmeier A; Sager HB; Joner M; Fusaro M; Richardt G; Laugwitz KL; Neumann FJ; Schunkert H; Schüpke S; Kastrati A JAMA Cardiol; 2021 Oct; 6(10):1121-1129. PubMed ID: 34190967 [TBL] [Abstract][Full Text] [Related]
13. A Prospective, Randomized, Open-Label, Blinded, Endpoint Study Exploring Platelet Response to Half-Dose Prasugrel and Ticagrelor in Patients with the Acute Coronary Syndrome: HOPE-TAILOR Study. Jin C; Kim MH; Bang J; Serebruany V Cardiology; 2017; 138(4):201-206. PubMed ID: 28810251 [TBL] [Abstract][Full Text] [Related]
14. Prasugrel in the treatment of acute coronary syndrome. Spartalis M; Tzatzaki E; Spartalis E; Paschou SA; Athanasiou A; Iliopoulos DC; Siasos G; Voudris V Future Cardiol; 2020 Nov; 16(6):559-568. PubMed ID: 32390477 [TBL] [Abstract][Full Text] [Related]
15. Physician and Hospital Utilization of P2Y12 Inhibitors in ST-Segment-Elevation Myocardial Infarction in the United States: A Study From the National Cardiovascular Data Registry's Research to Practice Initiative. Faridi KF; Garratt KN; Kennedy KF; Maddox TM; Secemsky EA; Butala NM; Yeh RW Circ Cardiovasc Qual Outcomes; 2020 Mar; 13(3):e006275. PubMed ID: 32156164 [TBL] [Abstract][Full Text] [Related]
16. Comparison of prasugrel and ticagrelor in patients with acute coronary syndrome undergoing percutaneous coronary intervention: A meta-analysis of randomized and non-randomized studies. Watti H; Dahal K; Zabher HG; Katikaneni P; Modi K; Abdulbaki A Int J Cardiol; 2017 Dec; 249():66-72. PubMed ID: 29121759 [TBL] [Abstract][Full Text] [Related]
17. Downstream or upstream administration of P2Y12 receptor blockers in non-ST elevated acute coronary syndromes: study protocol for a randomized controlled trial. Tarantini G; Mojoli M; Varbella F; Caporale R; Rigattieri S; Andò G; Cirillo P; Pierini S; Santarelli A; Sganzerla P; De Cesare N; Limbruno U; Lupi A; Ricci R; Cernetti C; Favero L; Saia F; Roncon L; Gasparetto V; Ferlini M; Ronco F; Ferri L; Trabattoni D; Russo A; Guiducci V; Penzo C; Tarantino F; Mauro C; Marchese A; Castiglioni B; La Manna A; Martinato M; Gregori D; Angiolillo DJ; Musumeci G Trials; 2020 Nov; 21(1):966. PubMed ID: 33234137 [TBL] [Abstract][Full Text] [Related]
18. Safety and Efficacy in Prasugrel- Versus Ticagrelor-Treated Patients With ST-Elevation Myocardial Infarction. Dimitroulis D; Golabkesh M; Naguib D; Knoop B; Dannenberg L; Helten C; Pöhl M; Jung C; Kelm M; Zeus T; Polzin A J Cardiovasc Pharmacol; 2018 Oct; 72(4):186-190. PubMed ID: 29985284 [TBL] [Abstract][Full Text] [Related]